Stock Analiz

Treace Medical Concepts, Inc. TMCI

Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026

$5.27Market cap $345M
Open the interactive analysis →

Treace Medical Concepts, Inc. (TMCI) is a healthcare company listed in the US with a market value of about $345M. In the twelve months to September 30, 2026 it had revenue of $203M and net income of -$56M, a net margin of -27.4%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 30% a year, a 5-year average ROIC of -20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 86% below the current price.

About Treace Medical Concepts

Treace Medical Concepts is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $39M in 2019 to $213M in 2025, growth of about 32.4% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 14% over three years (dilution for shareholders). It spends 10% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.7
P/B5.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-5.4%
Shareholder yield0.0%
Intrinsic value vs. price−86%

Growth and quality

Revenue growth (1 yr)1.6%
Revenue growth (5 yrs, per year)30.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-26.6%
ROIC (5-yr avg.)-20.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$203M$213M$209M$187M$142M$94M$57M$39M
Net income-$56M-$59M-$56M-$50M-$43M-$21M-$4M-$4M
Free cash flow-$19M-$29M-$49M-$46M-$45M-$20M-$6M-$9M
EPS (diluted)$-0.85$-0.93$-0.90$-0.81$-0.77$-0.43$-0.12$-0.13
Net margin-27.4%-27.7%-26.6%-26.5%-30.2%-21.8%-6.4%-10.8%
ROIC—-26.9%-24.1%-19.5%-21.3%-10.7%2.1%-88.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $6.17, 17% above the current price; targets range from $5.00 to $7.00; the consensus rating is “Buy”; expected EPS is $-0.81 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Treace Medical Concepts stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 86% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Treace Medical Concepts pay a dividend?

Not currently.

Is Treace Medical Concepts a good stock to buy?

We do not give buy or sell advice. Treace Medical Concepts scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.